Literature DB >> 22080202

Encephalopathy, disseminated intravascular coagulation, and hemolytic-uremic syndrome after infection with enterohemorrhagic Escherichia coli O111.

Sadaya Matano1, Katsuhisa Inamura, Michio Konishi, Toshiya Okumura, Hiroshi Kawai, Toshiyuki Okamura, Yoshiko Takata, Keiko Yamada, Misato Obata, Hajime Nagata, Yoshiko Muramoto, Tatsuho Sugimoto.   

Abstract

An outbreak of enterohemorrhagic Escherichia coli (EHEC) occurred in Toyama and other prefectures in Japan during 2011. Some patients, including adults, showed complications such as encephalopathy, disseminated intravascular coagulation, and hemolytic-uremic syndrome, and the disease course was extremely aggressive. This report describes the clinical features of four patients infected with Escherichia coli (E. coli) O111 who developed very severe to fatal complications. The initial symptoms in all patients included abdominal pain, diarrhea, and bloody stools, and neurological abnormalities started to appear from 1 to 3 days after admission. Vomiting and pyrexia developed in three patients. Leukocyte counts, lactate dehydrogenase (LDH), and fibrin/fibrinogen degradation products were elevated, and thrombocytopenia was evident. Extremely elevated LDH and severe thrombocytopenia were characteristic at the time encephalopathy became apparent. All patients received oral fosfomycin, intravenous antibiotics, and anticoagulant therapy, three received gamma globulin, plasma exchange, and blood transfusion, and two received steroids and dialysis. Three patients required mechanical ventilation, and two adult patients died. E. coli O111 positive for Shiga toxin 2 was detected in stool culture in two patients, and serological tests for E. coli O111 were positive in the other two patients. In conclusion, EHEC O111 can cause severe illness in children and adults, and the prognosis becomes poorer as the severity of complications increases. Close monitoring including platelet counts and LDH are useful. Once these clinical parameters change, intensive treatment should be provided to prevent the development of severe complications.

Entities:  

Mesh:

Year:  2011        PMID: 22080202     DOI: 10.1007/s10156-011-0336-9

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  7 in total

1.  The Polymorphic Aggregative Phenotype of Shiga Toxin-Producing Escherichia coli O111 Depends on RpoS and Curli.

Authors:  M E Diodati; A H Bates; W G Miller; M Q Carter; Y Zhou; M T Brandl
Journal:  Appl Environ Microbiol       Date:  2015-12-28       Impact factor: 4.792

Review 2.  Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.

Authors:  Andreas Bauwens; Josefine Betz; Iris Meisen; Björn Kemper; Helge Karch; Johannes Müthing
Journal:  Cell Mol Life Sci       Date:  2012-07-06       Impact factor: 9.261

3.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

4.  Investigation of encephalopathy caused by Shiga toxin 2c-producing Escherichia coli infection in mice.

Authors:  Muhammad Yunus Amran; Jun Fujii; Satoshi O Suzuki; Glynis L Kolling; Sharon Y A M Villanueva; Mosaburo Kainuma; Hideyuki Kobayashi; Hideko Kameyama; Shin-ichi Yoshida
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

5.  Campylobacter bacteremia in hemodialysis patients by eating raw meat - the importance of sanitary education.

Authors:  Yoshio Shimizu; Arisa Ishii; Akiko Takahata; Tadahiro Kajiyama; Aya Yamahatsu; Hiroaki Io; Atsushi Kurusu; Chieko Hamada; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Case Rep Nephrol Urol       Date:  2012-10-24

6.  The critical role of lipopolysaccharide in the upregulation of aquaporin 4 in glial cells treated with Shiga toxin.

Authors:  Naotoshi Sugimoto; Hue Leu; Natsumi Inoue; Masaki Shimizu; Tomoko Toma; Mondo Kuroda; Takekatsu Saito; Taizo Wada; Akihiro Yachie
Journal:  J Biomed Sci       Date:  2015-09-18       Impact factor: 8.410

7.  Hemolytic Uremic Syndrome: An Increasingly Recognized Public Health Problem.

Authors:  Takuya Murakami; Tetsu Akimoto; Tomoyuki Yamazaki; Hiromichi Yoshizawa; Mari Okada; Atsushi Miki; Saki Nakagawa; Ken Ohara; Taro Sugase; Takahiro Masuda; Takahisa Kobayashi; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2018-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.